R&D Views & Analysis | pharmaphorum

Views & Analysis

Patient centricity makes ethical and commercial sense

Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense.

Views & Analysis

The user experience in your clinical trials: it really matte...

Everybody knows the current clinical trial model is broken. But it’s not technology that will fix it – it’s a mindset shift towards seeing clinical trials through the ‘user’s’ eyes.

R&D

Survey: patient engagement a low priority in clinical trials

To what extent is patient engagement really valued and acted upon by pharma companies, CROs and hospitals – and what are the most effective methods to retain participants in clinical trials?

Views & Analysis

Digital Health Round-Up: Novartis and Science 37 hope to cut...

Richard Staines presents a round-up of the week’s digital health news

Views & Analysis

3d rendering robot working with digital display

The third wave of AI in pharma R&D

The capabilities of artificial intelligence are advancing and its 'third wave' offers the ability to analyse enormous sets of data, identify patterns, and generate algorithms to explain them, t

Debates & Insight

Paid medicine. Cost of treatment. Isolated 3D image

Pricing and Market Access Outlook 2018

This year’s edition of Pricing and Market Access Outlook, our first as IQVIA, identifies a trend towards models that reward value and outcomes.

Patient centricity makes ethical and commercial sense

The user experience in your clinical trials: it really matte...

Survey: patient engagement a low priority in clinical trials

Digital Health Round-Up: Novartis and Science 37 hope to cut...

The third wave of AI in pharma R&D

Pricing and Market Access Outlook 2018

Hims & Hers buys Australian digital health firm for $1.15bn

How to meet your physicians where they are online

Views & Analysis

Editor's Picks